We are particularly interested in the mechanisms underlying and strategies for targeting residual tumors that persist following chemotherapy and/or targeted therapy. Our research has provided insights into how driver oncogenes maintain the neoplastic state, how residual tumors emerge after treatment, and how to target survival mechanisms to eradicate these persistent cancer cells (Li et al., Cancer Cell, 2014; Liu et al., J Hematol Oncol, 2019; Azizian et al., J Hematol Oncol, 2020; Du et al., BMC Cancer, 2021; Liu et al., Nat Commun, 2022; Deutzmann et al., Nat Commun, 2024). Ongoing projects explore various stress response and cell death pathways as potential therapeutic vulnerabilities in residual tumors.
